Daniel O’Day snatches another I/O company, buying half of a pioneering cancer drug discoverer's biotech

Jason Mast

Editor

Gilead CEO Daniel O’Day has nabbed another immuno-oncology partner in his quest to remake the biotech’s cancer division, inking an up-to $1.5 billion deal with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Daniel O’Day snatches another I/O company, buying half of a pioneering cancer drug discoverer's biotech

Jason Mast

Editor

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Biotech seed rounds sink to lowest level in years as industry slump drags on

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Daniel O’Day snatch­es an­oth­er I/O com­pa­ny, buy­ing half of a pi­o­neer­ing can­cer drug dis­cov­er­er's biotech

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Daniel O’Day snatches another I/O company, buying half of a pioneering cancer drug discoverer's biotech